Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2012

01.07.2012 | Article

Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis

verfasst von: A. Burkett, K. L. Vandemheen, T. Giesbrecht-Lewis, K. Ramotar, W. Ferris, F. Chan, S. Doucette, D. Fergusson, S. D. Aaron

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Our objective was to describe the natural history of infection with transmissible and unique strains of P. aeruginosa (PA) in adult CF patients and to determine if clearance of PA from sputum was associated with an improvement in clinical status. This was a 3-year prospective cohort study of adult patients with CF. Sputum was collected at baseline and annually. Rate of decline of FEV1, BMI, exacerbation rate, and time to death or transplant were compared between patients who cleared PA versus those in whom PA was persistent. A total of 373 patients were included in the study, 75% were infected with PA at baseline; 24% were infected with transmissible strains and 51% with unique strains. Patients infected with unique strains were more likely to clear PA from their sputum over 3 years compared to those infected with transmissible strains (19% vs 10%, P = 0.05). Declines in FEV1 and rates of pulmonary exacerbations, deaths, or lung transplants were not different between patients who cleared PA compared to those who remained persistently infected. No clinical benefit was identified in patients who cleared PA from sputum compared to those who remained persistently infected.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4(1):35–51PubMed Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4(1):35–51PubMed
2.
Zurück zum Zitat Corey M, Farewell V (1996) Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 143(10):1007–1017PubMedCrossRef Corey M, Farewell V (1996) Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 143(10):1007–1017PubMedCrossRef
3.
Zurück zum Zitat Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34(2):91–100PubMedCrossRef Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34(2):91–100PubMedCrossRef
4.
Zurück zum Zitat Aaron SD, Vandemheen KL, Ramotar K et al (2010) Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 304(19):2145PubMedCrossRef Aaron SD, Vandemheen KL, Ramotar K et al (2010) Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 304(19):2145PubMedCrossRef
5.
Zurück zum Zitat Al-Aloul M, Crawley J, Winstanley C et al (2004) Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59(4):334–336PubMedCrossRef Al-Aloul M, Crawley J, Winstanley C et al (2004) Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59(4):334–336PubMedCrossRef
6.
Zurück zum Zitat Cheng K, Smyth RL, Govan JR et al (1996) Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348(9028):639–642PubMedCrossRef Cheng K, Smyth RL, Govan JR et al (1996) Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348(9028):639–642PubMedCrossRef
7.
Zurück zum Zitat Jones AM, Dodd ME, Morris J et al (2010) Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest 137(6):1405–1409PubMedCrossRef Jones AM, Dodd ME, Morris J et al (2010) Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest 137(6):1405–1409PubMedCrossRef
8.
Zurück zum Zitat Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951PubMedCrossRef Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951PubMedCrossRef
9.
Zurück zum Zitat Frederiksen B, Koch C (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23(5):330–335PubMedCrossRef Frederiksen B, Koch C (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23(5):330–335PubMedCrossRef
10.
Zurück zum Zitat Ratjen F, Munck A, Kho P, Angyalosi G (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4):286–291PubMedCrossRef Ratjen F, Munck A, Kho P, Angyalosi G (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4):286–291PubMedCrossRef
11.
Zurück zum Zitat Crapo R, Morris A (1981) Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 123(6):659–664PubMed Crapo R, Morris A (1981) Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 123(6):659–664PubMed
12.
Zurück zum Zitat Altman E, Wang Z, Aaron SD et al (2009) Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance. J Microbiol Methods 76(2):204–208PubMedCrossRef Altman E, Wang Z, Aaron SD et al (2009) Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance. J Microbiol Methods 76(2):204–208PubMedCrossRef
13.
Zurück zum Zitat Beaudoin T, Aaron SD, Giesbrecht-Lewis T, Vandemheen K, Mah TF (2010) Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada. Can J Microbiol 56(7):548–557PubMedCrossRef Beaudoin T, Aaron SD, Giesbrecht-Lewis T, Vandemheen K, Mah TF (2010) Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada. Can J Microbiol 56(7):548–557PubMedCrossRef
14.
Zurück zum Zitat Ojeniyi B, Høiby N, Rosdahl VT (1991) Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients. APMIS 99(2):187–195PubMedCrossRef Ojeniyi B, Høiby N, Rosdahl VT (1991) Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients. APMIS 99(2):187–195PubMedCrossRef
15.
Zurück zum Zitat Hoiby N, Koch C (1990) Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 45(11):881–884PubMedCrossRef Hoiby N, Koch C (1990) Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 45(11):881–884PubMedCrossRef
16.
Zurück zum Zitat Permin H, Koch C, Høiby N et al (1983) Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 12(Suppl A3):313–323PubMed Permin H, Koch C, Høiby N et al (1983) Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 12(Suppl A3):313–323PubMed
17.
Zurück zum Zitat Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD (2010) Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol 48(1):78–86PubMedCrossRef Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD (2010) Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol 48(1):78–86PubMedCrossRef
18.
Zurück zum Zitat Aaron SD, Kottachchi D, Ferris WJ et al (2004) Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 24(4):631–637PubMedCrossRef Aaron SD, Kottachchi D, Ferris WJ et al (2004) Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 24(4):631–637PubMedCrossRef
19.
Zurück zum Zitat Taccetti G, Campana S, Festini F, Mascherini M, Döring G (2005) Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26(3):458–461PubMedCrossRef Taccetti G, Campana S, Festini F, Mascherini M, Döring G (2005) Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26(3):458–461PubMedCrossRef
Metadaten
Titel
Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis
verfasst von
A. Burkett
K. L. Vandemheen
T. Giesbrecht-Lewis
K. Ramotar
W. Ferris
F. Chan
S. Doucette
D. Fergusson
S. D. Aaron
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2012
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1483-8

Weitere Artikel der Ausgabe 7/2012

European Journal of Clinical Microbiology & Infectious Diseases 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.